Boundless Bio, Inc., biopharma company, develops therapies and medicines for the treatment of cancers. It offers therapeutics based on extrachromosomal DNA (ecDNA) one of the drivers of the aggressive cancers, such as cancers characterized by high copy number amplification of oncogenes. The company was formerly known as Pretzel Therapeutics, Inc. Boundless Bio, Inc. was founded in 2018 and is based in LA Jolla, California.
Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing novel treatments for advanced liver diseases. Founded in 2019, the company aims to address conditions such as liver fibrosis, cirrhosis, and liver cancer, particularly targeting Claudin-1 positive tumors and organ fibrosis. Alentis employs a research platform that utilizes clinically relevant readouts and single-cell RNA sequencing of patient liver tissues, enabling the development of effective therapies to combat fibrosis and reverse the progression of these diseases. Through its innovative approach, Alentis Therapeutics seeks to improve outcomes for patients suffering from severe liver-related health issues.
Cerebral Therapeutics, Inc. is a pharmaceutical company that develops implanted drug-device combination therapies for the treatment of neurologic diseases. The company uses implanted, refillable catheter and pump system to deliver a continuous intracerebroventricular (ICV) dose for the formulation of anti-epileptic drug valproic acid, called CT-010, to treat refractory epilepsy. Cerebral Therapeutics, Inc. was formerly known as Cerebral Therapeutics LLC. The company was incorporated in 2010 and is based in Aurora, Colorado.
Ventus Therapeutics U.S., Inc. is a biopharmaceutical company based in Natick, Massachusetts, with an additional location in Montreal, Canada. Founded in 2019, it focuses on discovering and developing novel small-molecule medicines that target the innate immune system to address autoimmune diseases, inflammatory diseases, and cancer. The company employs a structural immunology platform that integrates protein engineering to elucidate molecular structures and mechanisms of action. This platform facilitates the development of precise binding and functional screening assays, as well as structure-based modeling. Ventus Therapeutics is advancing an emerging pipeline of drug programs aimed at key targets within the innate immune system, leveraging its proprietary capabilities in rational and structure-based drug design.
DiCE Therapeutics, founded in 2013 and based in Menlo Park, California, specializes in developing a platform for the discovery of novel small molecules aimed at targets that have previously been difficult to address in the pharmaceutical sector. The company utilizes innovative technology that extends directed evolution, allowing for the direct translation of DNA-encoded information into organic compounds, thereby streamlining the traditionally labor-intensive processes of medicinal chemistry. This platform not only serves the pharmaceutical industry but also has applications in agriculture and materials sciences. The founding team includes notable figures such as Stanford Professor Pehr Harbury, who developed the core technology, and other experienced professionals from various sectors, contributing to the company's mission of transforming drug discovery and development.
Exo is a medical device startup handheld ultrasound platform and AI for imaging and therapeutic applications. The company is committed to delivering affordable and easy-to-use medical imaging to healthcare professionals around the world. By delivering easy-to-use, high-quality medical imaging. Exo empowers healthcare professionals to make critical, real-time decisions that improve patient outcomes. The Exo ultrasound platform combines advances in nano-materials, novel sensor technologies, advanced signal processing, and computation with the economies of scale of semiconductor manufacturing to dramatically reduce the cost of imaging. It also represents a giant leap in imaging and therapeutics technology one that will drive the development of high-performance products that are accessible, easy-to-use, and available at a price point never before possible.
Element Biosciences, Inc. develops genetic analysis tools for the research and diagnostic markets. The company provides a disruptive DNA sequencing technology and a sequencing platform, such as surface chemistry, sequencing chemistry, detection, and data analysis. The company was incorporated in 2017 and is based in San Diego, California.
NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and located in Wilmington, Delaware. The company is dedicated to discovering and developing innovative small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. By employing a discovery approach that leverages target structure biology and structure-based drug design, NiKang Therapeutics aims to facilitate the rapid and efficient development of proprietary drug candidates with optimal pharmacological properties. The company seeks to enhance the treatment options available to healthcare providers, ultimately improving patient outcomes in the fight against cancer.
Ceribell, Inc. specializes in the design and manufacture of medical devices aimed at acquiring and interpreting electroencephalography (EEG) data for patients with neurological conditions. The company offers the Ceribell EEG System, which includes a versatile EEG headband accommodating various hair types and head sizes, and a compact, battery-operated EEG recorder that delivers clinical-quality data with an on-device display. Ceribell focuses on improving the accessibility and efficiency of EEG technology by developing an FDA-cleared instant EEG system that can be set up by any healthcare provider in just six minutes, eliminating the need for specialized technologists. This system features a unique Brain Stethoscope function that converts brainwaves into sound, allowing for the detection of seizures through auditory means. By facilitating earlier diagnoses and targeted treatments for seizures, including non-convulsive seizures, Ceribell aims to enhance patient outcomes while reducing risks such as mortality and complications. Founded in 2014 and based in Mountain View, California, Ceribell is committed to transforming the diagnosis and management of serious neurological conditions in acute care settings.
Invivyd is a biotechnology company focused on developing advanced antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and other potentially emerging coronaviruses. Founded in 2020 and headquartered in Waltham, Massachusetts, the company aims to create best-in-class therapeutic and prophylactic treatments that surpass the efficacy of existing antibody programs. Its innovative portfolio features multiple non-competing antibodies, each targeting distinct viral epitopes, which is designed to minimize the risk of viral escape. By leveraging cutting-edge antibody discovery technologies, Invivyd seeks to enhance the potency and durability of its antibody candidates, addressing a critical need in the ongoing fight against coronaviruses.
Century Therapeutics, Inc. is a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-based therapies for cancer treatment. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company aims to create allogeneic living drugs that specifically target both hematologic and solid tumors. By utilizing iPSCs, Century Therapeutics can engineer immune effector cells through multiple rounds of cellular modification, producing master cell banks that can be expanded and differentiated for therapeutic use. Their innovative approach incorporates advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, along with Allo-Evasion technology, which helps prevent rejection by the host immune system. These advancements position Century Therapeutics to enhance the effectiveness and accessibility of cancer treatments.
Tenaya Therapeutics is a biotechnology company based in South San Francisco, California, focused on developing innovative therapies for heart disease, particularly heart failure. Established in 2016, the company employs three main platforms to address the underlying causes of heart disease: a cellular regeneration platform that reprograms cardiac fibroblasts into cardiomyocytes using proprietary transcription factors, a gene therapy platform for targeted delivery of therapeutic payloads, and a precision medicine approach tailored to individual patients. Through these platforms, Tenaya Therapeutics aims to enable the regeneration of heart tissue and tackle various forms of cardiomyopathies, leveraging advanced research in cardiac development and regeneration.
Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.
Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing therapeutics to address significant unmet medical needs. The company utilizes a novel platform for proteome-wide small molecule drug discovery, which combines proteomic techniques and synthetic chemistry to enhance drug selectivity and broaden the range of druggable proteins. Originating from research at The Scripps Research Institute, Vividion's technology enables the creation of detailed drug interaction maps, facilitating simultaneous target engagement and comprehensive selectivity profiling. By advancing its innovative synthetic and proteomic chemistry approaches, Vividion aims to deliver transformative treatments for patients with serious illnesses.
Cyteir Therapeutics, Inc. focuses on developing innovative therapeutics that harness the biology of DNA repair to treat cancer and address autoimmune diseases through synthetic lethality. The company manufactures targeted therapeutics designed to induce the self-destruction of diseased cells by overwhelming them with DNA damage. Utilizing an integrated drug development platform, Cyteir aims to balance DNA damage and repair mechanisms to achieve therapeutic effects. Its diverse pipeline includes small molecule therapeutics intended for various applications, particularly in hematological malignancies, solid tumors, and chronic autoimmune disorders. Founded in 2012 and headquartered in Lexington, Massachusetts, Cyteir Therapeutics is committed to overcoming significant challenges in oncology, such as minimizing side effects, reducing therapy resistance, and promoting the self-destruction of cancerous cells.
TScan Therapeutics is a biopharmaceutical company dedicated to developing innovative T cell therapies to treat various cancers, including liquid tumors and solid tumors. The company focuses on engineering T cell receptor (TCR) therapies, with specific candidates aimed at addressing hematologic malignancies and preventing relapse after hematopoietic stem cell transplantation. TScan utilizes a specialized platform that identifies shared T cell antigens and minimizes off-target effects, enhancing the safety and effectiveness of its treatments. The company’s pipeline includes both liquid tumor therapies and multiplexed TCR-T candidates for solid tumors. Founded in 2018, TScan Therapeutics is headquartered in Waltham, Massachusetts, and comprises a team of experts committed to expanding treatment options for patients with limited therapeutic alternatives.
DiCE Therapeutics, founded in 2013 and based in Menlo Park, California, specializes in developing a platform for the discovery of novel small molecules aimed at targets that have previously been difficult to address in the pharmaceutical sector. The company utilizes innovative technology that extends directed evolution, allowing for the direct translation of DNA-encoded information into organic compounds, thereby streamlining the traditionally labor-intensive processes of medicinal chemistry. This platform not only serves the pharmaceutical industry but also has applications in agriculture and materials sciences. The founding team includes notable figures such as Stanford Professor Pehr Harbury, who developed the core technology, and other experienced professionals from various sectors, contributing to the company's mission of transforming drug discovery and development.
Vivace Therapeutics, Inc. is a small molecule discovery and development company focused on creating innovative cancer therapeutics by targeting the Hippo pathway, which plays a critical role in tissue regeneration and organ development. Founded in 2014, the company is based in San Mateo, California, and operates with a commitment to advancing novel therapies that can improve outcomes for cancer patients. Vivace Therapeutics emphasizes a capital-efficient and modality-indifferent approach, collaborating with leading academic laboratories to leverage cutting-edge research. Its experienced management team and top-tier scientists aim to develop treatments that can be used independently or in combination with existing therapies, ultimately striving to enhance the lives of individuals affected by cancer.
Edgewise Therapeutics is a clinical-stage biopharmaceutical company based in Boulder, Colorado, specializing in the development of small molecule therapies for severe musculoskeletal diseases. Founded in 2017, the company leverages its expertise in skeletal muscle physiology to create innovative treatments for genetically defined muscle disorders, including Duchenne, Becker, and limb girdle muscular dystrophies. Edgewise Therapeutics employs a precision medicine platform to identify and target key muscle proteins and modulators, aiming to address the underlying causes of these conditions. Additionally, the company has established a state-of-the-art research facility to enhance its capabilities in understanding muscle adaptation and injury related to disease.
Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, focused on developing patient-specific immunotherapies to treat cancer. Founded in 2016, the company creates personalized vaccines and T cell therapies that harness the immune system to target and eliminate cancer cells. By identifying truncal tumor neo-antigens and other cancer-specific markers, Achilles Therapeutics aims to develop next-generation therapies that selectively attack tumors while sparing healthy tissues. Currently, the company is conducting two clinical trials: the CHIRON trial for patients with non-small-cell lung cancer and the THETIS trial for those with recurrent or metastatic melanoma.
Olema Oncology is a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for women's cancers, particularly estrogen receptor (ER)-positive breast cancer. The company's lead candidate, OP-1250, is an ER antagonist and selective ER degrader currently undergoing Phase 1/2 clinical trials for the treatment of metastatic or locally advanced, ER-positive, and human epidermal growth factor receptor 2-negative breast cancer. Olema's research focuses on utilizing its expertise in endocrine-driven cancers and the molecular mechanisms of the ER to create more effective treatments that aim to improve patient outcomes. In addition to OP-1250, Olema is advancing another drug candidate, OP-3136, further enriching its pipeline. Established in 2006 and headquartered in San Francisco, California, Olema is committed to transforming the standard of care for women facing these challenging diagnoses.
Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing tissue-targeted therapeutics for cancer, chronic viral infections, and other serious diseases. The company's lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial. It is a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, specifically targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, a preclinical candidate that targets Nectin4, expressed in various cancers, and SBT8230, aimed at treating chronic hepatitis B virus infection. Utilizing its proprietary ImmunoTAC technology, Silverback aims to develop a new generation of therapies that can be systemically delivered yet act locally at disease sites, thereby modulating critical disease pathways that were previously considered inaccessible.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers. Its mission is to expand the reach of targeted therapeutics by developing products for underserved populations.
The company utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine. Its programs include candidates in preclinical development for cancers that are driven by specific oncogenic alterations in either the BRAF kinase gene or in the FGFR2 and FGFR3 kinase genes.
Suzhou Connect Biopharmaceuticals, Ltd., a clinical-stage company, discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products in pipeline includes CBP-307, an orally-active, second-generation S1P1 agonist for the treatment of a range of autoimmune diseases, including inflammatory bowel disease, graft-versus-host disease, psoriasis, and multiple sclerosis; CBP-174 for allergic rhinitis and atopic dermatitis; and CBP-201, a novel monoclonal antibody for the treatment of atopic dermatitis, asthma, and other types of allergic inflammation. The company is headquartered in Taicang, China with operations in Melbourne and San Diego.
Bolt Biotherapeutics is a biotechnology company focused on developing innovative cancer treatments through its Boltbody platform, which centers on immune-stimulating antibody conjugates (ISAC). This platform combines tumor-targeting antibodies with potent immune stimulants, such as TLR agonists, to transform cold tumors into immunologically active ones and facilitate tumor elimination. One of the company's key developments is BDC-1001, designed as a monotherapy for patients with HER2-expressing solid tumors. Founded in 2015 and headquartered in Redwood City, California, Bolt Biotherapeutics aims to advance cancer immunotherapy and improve patient outcomes. The company was previously known as Bolt Therapeutics before rebranding in July 2015.
Everest Medicines Limited, a clinical-stage biopharmaceutical company, focuses on licensing, developing, and commercializing therapies for addressing critical unmet medical needs in Greater China and other Asia Pacific markets. It has a portfolio of eight clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal disease, and infectious diseases. The company was founded in 2017 and is headquartered in Shanghai, China.
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company that specializes in developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. Utilizing its proprietary XTreo technology platform, the company aims to deliver medications directly to affected tissues for extended periods with a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy specifically for chronic rhinosinusitis. The active ingredient in these formulations is mometasone furoate, which is recognized for its efficacy and safety in various FDA-approved therapies. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics was formerly known as 480 Biomedical, Inc. before rebranding in July 2018.
Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule, tumor-agnostic therapies. The company's lead product candidate, BDTX-189, is designed to inhibit specific mutations in ErbB kinases, including the epidermal growth factor receptor. Additionally, Black Diamond is advancing a pipeline of allosteric-EGFR mutation inhibitors and other early-stage programs targeting allosteric mutations in kinases associated with cancer and rare genetic diseases. The company employs a technology platform known as Mutation-Allostery-Pharmacology, which aims to address undrugged mutations in patients with genetically defined cancers. Founded in 2014 and based in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its rebranding in 2018.
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. The company's lead product candidate, ARQ-151, is a topical cream formulation of roflumilast currently undergoing Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. In addition, Arcutis is advancing ARQ-154, a topical foam formulation of ARQ-151 aimed at treating seborrheic dermatitis and scalp psoriasis, as well as ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory skin conditions. Another candidate, ARQ-255, is being developed to penetrate deeper into the skin to address inflammation in alopecia areata. Founded in 2016 and located in Westlake Village, California, Arcutis Biotherapeutics was formerly known as Arcutis, Inc. before its name change in October 2019.
Sojournix, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, focused on developing innovative therapies for women's health and neuroendocrine disorders. Founded in 2016, the company is advancing SJX-653, a selective neurokinin-3 antagonist designed as a non-hormonal treatment for moderate to severe vasomotor symptoms associated with menopause. By aiming to provide safe and effective alternatives to current treatment options, Sojournix seeks to improve healthcare outcomes for women suffering from these conditions.
Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. Operating in the United Kingdom, European Union, and the United States, Orchard employs an autologous ex vivo gene therapy approach to transform patients’ hematopoietic stem cells into gene-modified products for treatment through a single administration. Its portfolio includes Strimvelis, the first approved gene therapy for adenosine deaminase-severe combined immunodeficiency (ADA-SCID), along with several products in clinical development targeting metachromatic leukodystrophy, Wiskott-Aldrich syndrome, X-linked chronic granulomatous disease, and transfusion-dependent beta-thalassemia. The company also has a robust preclinical pipeline addressing various mucopolysaccharidosis types. Orchard collaborates with leading institutions in gene therapy, enhancing its research capabilities and clinical programs. Founded in 2015, Orchard Therapeutics continues to demonstrate a commitment to transforming the lives of patients through its advanced therapies.
Farcast is a clinical diagnostic company dedicated to providing personalized cancer treatment solutions. Its core technology utilizes a human tumor microenvironment to enable oncologists and drug developers to assess individual tumors and determine their treatment response profiles. This innovative approach aims to surpass traditional biomarker-guided strategies, thereby enhancing access to personalized medicine and improving the clinical management of cancer. Headquartered in Boston, Massachusetts, Farcast also operates a laboratory in Bangalore, India, reflecting its commitment to advancing cancer care through cutting-edge technology.
Synthorx, Inc. is a biopharmaceutical company based in La Jolla, California, that specializes in developing innovative protein therapeutics through synthetic biology. The company focuses on creating novel cytokine Synthorin programs aimed at treating cancer and autoimmune disorders. Its lead candidate, THOR-707, is a modified version of recombinant human IL-2 being tested for various solid tumors, both as a monotherapy and in combination with immune checkpoint inhibitors. Additionally, Synthorx is developing Synthorins for other indications, including IL-10 for immuno-oncology and IL-15 as an immunoregulatory cytokine. The company leverages proprietary engineered organisms to produce these advanced proteins with high fidelity, enhancing their efficacy, safety, and convenience for patients. Founded in 2014 with technology licensed from The Scripps Research Institute, Synthorx has attracted investment from various venture capital firms and operates as a subsidiary of Sanofi.
Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body.
The company was founded in 2013 and is headquartered in Connecticut, United States.
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a severe genetic disorder primarily affecting boys. The company's lead candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in muscle tissues. In addition to SGT-001, Solid Biosciences is advancing Anti-LTBP4, a monoclonal antibody designed to mitigate fibrosis and inflammation by targeting the LTBP4 protein. The company also works on developing biomarkers and wearable assistive devices under the Solid Suit program, which aims to provide therapeutic benefits to patients. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to further develop and commercialize gene therapies for DMD. The company’s initiatives address a critical need, as there are currently no effective cures or satisfactory treatments for this progressive and life-threatening condition.
Spero Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializes in developing novel therapies for multi-drug resistant (MDR) bacterial infections and rare diseases. Its key product candidates include tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adults with MDR Gram-negative infections, and SPR206, an intravenous agent targeting MDR Gram-negative infections in hospital settings. Additionally, the company is advancing SPR720, an oral antibiotic designed for treating pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics has established various collaborations and license agreements to support the development and commercialization of its products, including partnerships with Meiji Seika Pharma, Everest Medicines, and the Bill & Melinda Gates Medical Research Institute. Founded in 2013, Spero aims to address the critical need for effective treatments against serious bacterial infections using innovative approaches and mechanisms.
Ivantis Inc. is dedicated to developing innovative treatments for primary open angle glaucoma, a condition affecting over 60 million people globally. The company has created an intracanalicular scaffold or implantable device designed to alleviate high intraocular pressure in patients, offering a less invasive and more effective therapeutic option. Founded in 2007 and based in Irvine, California, Ivantis also provides a Session Persistence Server, which safeguards telnet task workers against data loss due to network issues and ensures terminal emulation users maintain productivity across various devices and operating systems. As Ivantis advances its glaucoma treatment solutions, it aims to expand its focus to other debilitating ophthalmic diseases. The company primarily serves ophthalmology specialists in the United States, providing its solutions for use in clinical trials.
Shockwave Medical, Inc. is a medical device company that specializes in intravascular lithotripsy technology aimed at treating calcified plaque in patients with various cardiovascular diseases. The company has developed the Lithoplasty™ family of balloon dilatation catheters, which incorporate lithotripsy electrodes to enhance the compliance of rigid vascular and valvular lesions before low-pressure dilation. This approach minimizes injury to healthy tissue and addresses limitations associated with traditional revascularization technologies. Shockwave offers specific catheters for different applications, including M5 catheters for above-the-knee peripheral artery disease, C2 catheters for coronary artery disease, and S4 catheters for below-the-knee peripheral artery disease. The technology is designed to facilitate more effective angioplasty and improve stent delivery, as well as enhance native tissue preparation for trans-catheter aortic valve replacement. Founded in 2009 and headquartered in Santa Clara, California, Shockwave Medical serves interventional cardiologists, vascular surgeons, and interventional radiologists across the United States and internationally.
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. Founded in 2008, the company is headquartered in Research Triangle Park, North Carolina. G1 Therapeutics is advancing several investigational therapies, including trilaciclib, an intravenous cyclin-dependent kinase (CDK) 4/6 inhibitor, currently undergoing Phase 1b/2 trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. The company is also developing lerociclib, an oral CDK4/6 inhibitor, which is in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer. Additionally, G1 Therapeutics is progressing rintodestrant, an oral selective estrogen receptor degrader, currently in Phase I/2 trials. The company has partnered with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment in locally advanced breast cancer. G1 Therapeutics aims to improve treatment outcomes for cancer patients through its innovative therapeutic approaches.
Audentes Therapeutics is a clinical-stage biotechnology company dedicated to developing and commercializing gene therapy products for patients with serious, life-threatening rare diseases caused by single gene defects. The company is advancing several therapies, including AT132, currently in Phase I/II clinical trials for X-linked myotubular myopathy, and AT342, also in Phase I/II studies for Crigler-Najjar syndrome. Additionally, Audentes is exploring AT845 in preclinical studies for Pompe disease and AT307 for the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. The company is also working on vectorized antisense treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1. Collaborations include a partnership with Genethon for XLMTM treatments and an agreement with the University of Pennsylvania for Crigler-Najjar syndrome products. Founded in 2012 and headquartered in San Francisco, California, Audentes Therapeutics operates as a subsidiary of Astellas US Holding, Inc.
Aclaris Therapeutics is a clinical-stage biopharmaceutical company based in the United States, specializing in the development of innovative dermatologic and immunologic therapies. Founded by the team behind Vicept Therapeutics, Aclaris is dedicated to addressing significant unmet medical needs in dermatology and immunology, particularly in areas lacking FDA-approved treatments. The company operates in two main segments: therapeutics and contract research. The therapeutics segment focuses on creating novel drug candidates for immuno-inflammatory diseases, while the contract research segment generates revenue by providing laboratory services. Aclaris's pipeline includes drug candidates such as Zunsemetinib, an oral MK2 inhibitor, aiming to fill critical treatment gaps in the healthcare landscape.
Protagonist Pty Ltd is a biotechnology company based in Brisbane, Australia, focused on developing innovative therapeutics for inflammatory and metabolic conditions. The company specializes in discovering peptide and small molecule compounds that mimic or inhibit protein-protein interactions relevant to therapeutic applications. Protagonist Pty Ltd also aims to identify drug candidates for targets that have traditionally been resistant to small molecule discovery, creating arrays of molecules that explore biologically-relevant chemical diversity. Originally founded as Cytokine Mimetics Pty Ltd in 2001, it operates as a subsidiary of Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops peptide-based products to address unmet medical needs, particularly in hematology and gastroenterology. Protagonist Therapeutics has a portfolio that includes drug candidates in various stages of clinical trials for conditions such as beta-thalassemia and inflammatory bowel disease.
Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands, focused on the discovery and development of bispecific antibody therapeutics. The company's pipeline includes several promising candidates, notably MCLA-128, currently in phase 2 clinical trials for metastatic breast cancer; MCLA-117, in phase I trials for acute myeloid leukemia; and MCLA-158, also in phase I trials for solid tumors. Additionally, Merus is advancing other bispecific antibody candidates, including MCLA-129 and MCLA-145, in collaboration with various pharmaceutical partners. The company employs a unique technology called Oligoclonics, which enables the production of a mixture of therapeutic antibodies from a single cell clone, aimed at targeting common antigens. Merus has established partnerships to enhance its research capabilities, such as its collaboration with Caris Life Sciences for detecting NRG1 fusions in cancer patients. Founded in 2003, Merus is headquartered in Utrecht and is dedicated to developing innovative treatments for cancer.
Blueprint Medicines Corporation is a biopharmaceutical company that specializes in developing small molecule kinase inhibitors aimed at treating cancers and rare diseases driven by genomic abnormalities. The company’s pipeline includes avapritinib, which targets systemic mastocytosis and gastrointestinal stromal tumors, and BLU-263, an oral KIT inhibitor for indolent systemic mastocytosis and other mast cell disorders. Additionally, fisogatinib is in Phase I trials for advanced hepatocellular carcinoma, while pralsetinib targets RET-altered non-small cell lung cancer and medullary thyroid carcinoma. Other investigational compounds include BLU-782, aimed at treating fibrodysplasia ossificans progressive. Established in 2008 and based in Cambridge, Massachusetts, Blueprint Medicines utilizes its proprietary chemical library and Insights-to-Validation Platform to develop personalized therapies that address specific molecular drivers of cancer and the challenges posed by resistance mechanisms. The company has formed collaboration agreements with several pharmaceutical entities to enhance its research and development efforts.
Zipline Medical, Inc. specializes in the development and marketing of non-invasive skin closure solutions, specifically through its patented Zip Surgical Skin Closure product. This innovative technology addresses the need for rapid, easy-to-use skin closure in various medical fields, including electrophysiology, cardiology, orthopedics, dermatology, emergency medicine, plastic and reconstructive surgery, obstetrics and gynecology, and general surgery. The company's PRELOC™ technology platform is designed to provide uniform closure forces while reducing tension that can lead to scarring, aiming to combine the efficiency of staples with the aesthetic benefits of sutures. Founded in 2009 and based in Campbell, California, Zipline Medical operates as a subsidiary of Stryker Corporation, leveraging its location in Silicon Valley to draw on expertise in medical device research and development. The company's focus on enhancing surgical procedures through improved skin closure techniques positions it as a valuable player in the medical device industry.
Bellicum Pharmaceuticals is a clinical-stage biopharmaceutical company based in Houston, Texas, focused on developing innovative cellular immunotherapies for the treatment of hematological cancers and solid tumors. The company is advancing its product candidates, including BPX-601, an autologous GoCAR-T therapy aimed at solid tumors expressing prostate stem cell antigen, and BPX-603, a dual-switch GoCAR-T therapy targeting solid tumors that express human epidermal growth factor receptor 2. Bellicum utilizes its proprietary Chemical Induction of Dimerization technology platform, which allows for real-time control of immune system components to enhance therapeutic efficacy. The company collaborates with various institutions, including Adaptimmune Therapeutics and Baylor College of Medicine, to further its research and development efforts. Founded in 2004, Bellicum Pharmaceuticals continues to make strides in cancer treatment through its novel immunotherapeutic approaches.
Civitas Therapeutics is a biopharmaceutical company dedicated to developing therapies for pulmonary delivery. The company focuses on creating innovative treatments for central nervous system and respiratory disorders, with a particular emphasis on conditions such as multiple sclerosis and spinal cord injuries. Civitas Therapeutics aims to improve the health and quality of life for patients across the United States through its specialized drug delivery systems.
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company based in Redwood City, California, that specializes in the development, manufacture, and marketing of biosimilar therapeutics. It primarily targets the oncology and inflammatory disease markets with its product offerings. The company's flagship product, UDENYCA, is a biosimilar to Neulasta, designed to stimulate the production of granulocytes to enhance the body’s infection-fighting capabilities. Coherus is also advancing several other biosimilar candidates, including those for Humira and Enbrel, which have completed Phase III clinical studies. Additionally, the company is working on biosimilars for other biologics, including ranibizumab and aflibercept, as well as a small-molecule drug for metabolic conditions. Coherus BioSciences was founded in 2010 and has established various license agreements to support its product development initiatives.
Zipline Medical, Inc. specializes in the development and marketing of non-invasive skin closure solutions, specifically through its patented Zip Surgical Skin Closure product. This innovative technology addresses the need for rapid, easy-to-use skin closure in various medical fields, including electrophysiology, cardiology, orthopedics, dermatology, emergency medicine, plastic and reconstructive surgery, obstetrics and gynecology, and general surgery. The company's PRELOC™ technology platform is designed to provide uniform closure forces while reducing tension that can lead to scarring, aiming to combine the efficiency of staples with the aesthetic benefits of sutures. Founded in 2009 and based in Campbell, California, Zipline Medical operates as a subsidiary of Stryker Corporation, leveraging its location in Silicon Valley to draw on expertise in medical device research and development. The company's focus on enhancing surgical procedures through improved skin closure techniques positions it as a valuable player in the medical device industry.
Dicerna Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of innovative treatments primarily for liver-related diseases, including rare inherited conditions, chronic liver diseases, and viral infections. Utilizing its proprietary GalXC RNA interference technology, Dicerna focuses on silencing disease-causing genes to address various health issues. Key product candidates include nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B virus infection, and belcesiran for genetic liver disease, among others. The company's extensive research efforts also encompass treatments for cardiovascular diseases and neurodegeneration. Dicerna has established strategic collaborations with prominent pharmaceutical companies to enhance its development capabilities. Founded in 2006 and headquartered in Lexington, Massachusetts, Dicerna is at the forefront of advancing RNA-based therapeutics.
T2 Biosystems, Inc. is an in vitro diagnostics company based in Lexington, Massachusetts, specializing in the development of diagnostic products for pathogen detection and biomarker analysis. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers a range of diagnostic solutions that can analyze various unpurified patient samples such as blood, saliva, and urine without extensive sample preparation. Key products include the T2Dx Instrument, which detects pathogens linked to sepsis and Lyme disease, and specific panels like the T2Candida Panel for identifying Candida species, the T2Bacteria Panel for detecting bacterial pathogens, and the T2SARS-CoV-2 Panel for COVID-19 testing. T2 Biosystems is also developing additional panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with Canon U.S. Life Sciences and Allergan Sales for advancing its diagnostic offerings. Founded in 2006, T2 Biosystems aims to enhance diagnostic accuracy and speed in medical settings.